Checkpoint Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Checkpoint Therapeutics

14/08/2023 22:56

* Checkpoint Therapeutics Inc  CKPT.OQ  reported a quarterly
adjusted loss of $1.05​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 78 cents per share.
    * Revenue rose 72.2% to $31.00 thousand from a year ago;
analysts
expected $5.00 thousand. 
    * Checkpoint Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.05​.
    * The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Checkpoint Therapeutics Inc shares had fallen by 13.4%
this
quarter and lost 58.1% so far this year.
    * The company reported a quarterly loss of $16.52 million.
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:56 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.78          -1.05          Missed
 Mar. 31 2023      -1.07          -0.89          Beat
 Dec. 31 2022      -1.31          -2.29          Missed
 Sep. 30 2022      -1.47          -1.20          Beat